BEAT Therapeutics
BEAT TherapeuticsObjetivos de Desenvolvimento Social
We aim to deliver meaningful experiences through great design, awesome development and remarkable content.
BEAT Therapeutics
UPTEC Asprela I
BEAT Therapeutics is a biotech startup developing first-in-class therapies against hard-to-treat cancers. We leverage the DNA Damage Response (DDR) to unlock new therapeutic opportunities for cancer patients. Our lead drug candidate, under preclinical development, is a new-class small molecule that inhibits cancer cells DNA repair via disruption of a central pathway in homologous recombination (HR). The uniqueness of this candidate lies in its novel mechanism of action, acting with exceptional efficacy and precision, ensuring safety and effectively eliminating chemotherapy-resistant cells, making it a true advance in cancer treatment. We work with a steadfast commitment to patient well-being, striving to set new benchmarks in treatment efficacy, minimize side effects and drive progress in cancer treatment to enhance patients’ quality of life.